SCHEDULE 13G/A: Tang Capital Group Maintains 5.9% Stake in Tarsus Pharmaceuticals, Files Amended Schedule 13G

Tang Capital Management, LLC and its affiliated entities, including Kevin Tang, have filed an amended Schedule 13G, reaffirming their collective beneficial ownership of 5.90% of Tarsus Pharmaceuticals, Inc.'s common stock as of March 31, 2025.

Summary

• The filing is an Amendment No. 3 to Schedule 13G for Tarsus Pharmaceuticals, Inc. (Issuer: 87650L103).
• The reporting persons include Tang Capital Management, LLC, Kevin Tang, Tang Capital Partners, LP, Tang Capital Partners International, LP, Tang Capital Partners III, Inc., and Tang Capital Partners IV, Inc.
• As of March 31, 2025, the aggregate amount beneficially owned by the reporting group is 2,454,797 shares of Common Stock.
• This ownership represents 5.90% of Tarsus Pharmaceuticals, Inc.'s outstanding Common Stock.
• The percentage is calculated based on 41,580,162 shares of Common Stock outstanding as of February 29, 2025, as reported in the Issuer's Prospectus filed on Form 424B5 on March 13, 2025.
• All beneficially owned shares are held with shared voting and shared dispositive power among the reporting persons.
• The reporting persons certify that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer.

Sentiment

Score: 7

Explanation: The filing is a routine disclosure of beneficial ownership by a significant institutional investor, indicating a continued passive stake in the company. The explicit statement that the shares were not acquired for control purposes contributes to a stable outlook.

Positives

• A significant institutional investor, Tang Capital, continues to hold a substantial stake (5.90%) in Tarsus Pharmaceuticals, indicating ongoing investment interest.
• The filing explicitly states that the shares were not acquired for the purpose of changing or influencing control of the issuer, which suggests stability in corporate governance and a passive investment approach from this shareholder group.

Negatives

• NA

Risks

• NA

Future Outlook

NA (This document, a Schedule 13G, is a beneficial ownership report and does not provide future outlook or guidance.)

Management Comments

• NA (The document does not contain notable quotes or paraphrased statements from Tarsus Pharmaceuticals' management.)

Industry Context

NA (This document, a Schedule 13G, is a beneficial ownership report and does not provide industry context.)

Comparison to Industry Standards

• NA (This document, a Schedule 13G, is a beneficial ownership report and does not provide comparisons to industry standards or specific comparable companies/projects.)

Management Changes

Corporate Governance

Legal Proceedings

• NA (The document does not report any legal or regulatory matters.)

Related Party Transactions

• NA (The document does not disclose any related party dealings.)

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional holding, potentially reinforcing confidence in the company's investor base.
• Management: Confirms a passive investment stance from this major shareholder group, reducing immediate pressure related to control or activist demands.

Next Steps

• NA (The document does not specify future actions, events, or milestones for Tarsus Pharmaceuticals or the reporting persons beyond standard regulatory filing requirements.)

Key Dates

Recommendation

Keywords

Tarsus Pharmaceuticals, Tang Capital Management, Kevin Tang, Schedule 13G, beneficial ownership, common stock, institutional investor, SEC filing